FATE Fate Therapeutics, Inc. gains 28% Sep 20, 2017

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. Its novel ex vivo cell programming approach applies to modulate the therapeutic function and direct the fate of immune cells. The company's lead product candidate is ProTmune, a programmed immuno-regulatory cell therapy that is in clinical development stage for the prevention of acute graft-versus-host disease and cytomegalovirus infection in immunocompromised patients undergoing allogeneic hematopoietic cell transplantation. Its preclinical programs include NK- and T-cell cancer immunotherapies, such as off-the-shelf therapies derived from engineered induced pluripotent cells comprising iNK cell therapy and iT cell therapy; and a CD34+ cell immuno-regulatory therapy to suppress aberrant auto-reactive effector cells for autoimmune diseases. The company has a research collaboration and license agreement with Juno Therapeutics, Inc. to identify and apply small molecule modulators to enhance the therapeutic function of genetically-engineered chimeric antigen receptor T-cell and T-cell receptor immunotherapies. It has a partnership agreement with Memorial Sloan Kettering Cancer Center for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines; and an immunotherapy collaboration with the University of Minnesota. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California. http://www.priceseries.com/trade/FATE-Fate-Therapeutics-Inc-stock-gains-28-percent-a-Trade-Record-by-priceSeries-2017082820170920.html